Navigation Links
Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Date:6/11/2008

s or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in drug discovery and clinical development processes; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development, to expand commercialization activities or consummate acquisitions or to service or repay debt obligations; the accuracy of our estimations of the size of the market, and the potential market, for our products in specific disease areas; sales numbers and future guidance publicly provided by Boston Scientific Corporation regarding sales of their paclitaxel-eluting coronary stent products; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our pate
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
3. Vical Names Andrew de Guttadauro Vice President, Corporate Development
4. Signalife Provides Corporate Update
5. Biomira Announces Plan to Reincorporate in the United States
6. Pressure BioSciences, Inc. Provides Corporate Update
7. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
8. Clinsys Clinical Research, Inc. Announces Relocation of Corporate Headquarters
9. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... LOUIS , July 29, 2014  Sigma-Aldrich Corporation ... water and energy use, increased its investment in Green ... service around the world last year, the Company announced ... What if Science Changed the World? ... earned several honors for being a responsible corporate citizen, ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
(Date:7/29/2014)... July 29, 2014 Eppendorf Centrifuge ... product selection. Eppendorf 5427 R is geared towards high-end ... – it is targeted towards work requiring high sample ... R as it compliments their extensive 16, 48, and ... of microcentrifuge tubes, PCR tubes, PCR strip tubes, and ...
(Date:7/29/2014)... July 29, 2014 White papers ... and cloud based eClinical technologies, have been published by ... These follow a long line of white papers by ... including Life Science Leader, Pharmaceutical Online, and OpenHealthNews. , ... a paper by CTO Marc Desgrousilliers, 'The Five ...
Breaking Biology Technology:Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 2Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications 3
... Additional Phase 3 Trials on Track for Initiation Later ... for Today at 8:30 a.m. Eastern Time -, ... ARNA ) announced today that an independent Echocardiographic,Data Safety ... to stop,the ongoing pivotal Phase 3 trial, BLOOM (Behavioral ...
... Unit for $185 Million; Deal ... Expected to Close in the Fourth Quarter 2007, ... NABI ) announced today that it has entered into,a ... the Nabi,Biologics strategic business unit (SBU) to Biotest Pharmaceuticals,Corporation ...
... Ltd. (NASDAQ: XTLB ; LSE: XTL; TASE: XTL) ... 8:30 a.m. EDT to discuss the,Phase IIb clinical trial ... was initiated yesterday. Hosting the call will be ... will be two distinguished members of the diabetic,neuropathic pain ...
Cached Biology Technology:Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 2Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 3Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 4Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 5Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 6Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG 2Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG 3Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG 4Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG 5Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG 6Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2
(Date:7/29/2014)... Francisco is the first to show that while the ... aging, these negative effects may be reduced by maintaining ... "The study participants who exercised, slept well and ate ... didn,t maintain healthy lifestyles, even when they had similar ... assistant professor in the department of psychiatry at UCSF. ...
(Date:7/28/2014)... An international team of researchers led by the University ... rice. , The genetic information will enhance scientists, and ... as well as enable the development of new rice ... environmental stressors to help solve global hunger challenges. , ... Oryza glaberrima ) and evidence for independent domestication," was ...
(Date:7/28/2014)... School of Medicine have pinpointed a mechanism in part of ... the blood, linking it to both type 1 and type ... issue of Proceedings of the National Academies of Sciences ... located in a part of the hypothalamus known as ... motion that control glucose levels in the blood," said lead ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4Glucose 'control switch' in the brain key to both types of diabetes 2
... University Park, Pa. Health benefits from polyphenol antioxidants ... may come at a cost to some people. Penn ... the amount of iron the body absorbs, which can ... "Polyphenols have been known to have many beneficial effects ...
... biological invader that reaches its shores via cargo shipped ... Asian Longhorned Beetles, Kudzu, Triffid weed and others have ... harming human health and threatening biodiversity. The answer: ... of controlling invaders against the economic necessity of free ...
... brings debilitating side effects such as nausea, liver toxicity and ... way to deliver this life-saving therapy to cancer patients ― ... been invented by Dr. Dan Peer of Tel Aviv University,s ... Nano Science and Nano Technology together with Prof. Rimona Margalit ...
Cached Biology News:Polyphenol antioxidants inhibit iron absorption 2New analysis weighs lost trade, costs to control invasive species against economic damages 2New analysis weighs lost trade, costs to control invasive species against economic damages 3A cluster bomb for cancer care 2
US Pharmacopoeia Purified-Water/Water-for-Injection Quality Water...
... PinPoint™ Vector Sequencing Primer is designed for ... Vectors (Cat.# V2031, V2051, V2061). The primer ... at nucleotides 325343, approximately 4050 base pairs ... can be used to determine if an ...
Request Info...
...
Biology Products: